// App-Quantinova.ai

: Co-administration of low concentrations of matrix metalloproteinase 2, myosin light chain kinase and nitric oxide synthase inhibitors protects heart from ischemia/reperfusion injury

Researchers

Presenter

  • I. Bil-Lula

Principal Investigators

  • G. Sawicki

  • M. Wozniak

  • A. Krzywonos-Zawadzka

Medical Centers

  • Wroclaw Medical University, Department of Clinical Chemistry, Wroclaw, Poland

  • University of Saskatchewan, Department of Pharamcology, Saskatoon, Canada

Locations

  • Poland

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Central Nervous System (CNS)

Disease

  • N/A

Biomarkers

  • Myosin Heavy Chain 8

  • Lactate dehydrogenase

  • Matrix metalloproteinase 2

Drug/Treatment

  • Nitric oxide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • National Science Centre

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved